Innospec (IOSP) Q3 Earnings Meet Estimates

05.11.24 23:55 Uhr

Werte in diesem Artikel
Aktien

112,00 EUR 1,00 EUR 0,90%

Innospec (IOSP) came out with quarterly earnings of $1.35 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.59 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this specialty chemicals company would post earnings of $1.37 per share when it actually produced earnings of $1.39, delivering a surprise of 1.46%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Innospec, which belongs to the Zacks Chemical - Diversified industry, posted revenues of $443.4 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.45%. This compares to year-ago revenues of $464.1 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Innospec shares have lost about 11.6% since the beginning of the year versus the S&P 500's gain of 19.8%.What's Next for Innospec?While Innospec has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Innospec: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.43 on $457.25 million in revenues for the coming quarter and $5.92 on $1.83 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Diversified is currently in the bottom 17% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Another stock from the same industry, Air Products and Chemicals (APD), has yet to report results for the quarter ended September 2024. The results are expected to be released on November 7.This seller of gases for industrial, medical and other uses is expected to post quarterly earnings of $3.44 per share in its upcoming report, which represents a year-over-year change of +9.2%. The consensus EPS estimate for the quarter has been revised 0.8% higher over the last 30 days to the current level.Air Products and Chemicals' revenues are expected to be $3.19 billion, up 0% from the year-ago quarter.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Innospec Inc. (IOSP): Free Stock Analysis Report Air Products and Chemicals, Inc. (APD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Innospec

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Innospec

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Innospec IncShs

Analysen zu Innospec IncShs

DatumRatingAnalyst
09.11.2017Innospec NeutralMonness, Crespi, Hardt & Co.
22.08.2017Innospec BuyMonness, Crespi, Hardt & Co.
19.12.2016Innospec NeutralMonness, Crespi, Hardt & Co.
04.11.2016Innospec BuyMonness, Crespi, Hardt & Co.
12.10.2015Innospec NeutralMonness, Crespi, Hardt & Co.
DatumRatingAnalyst
22.08.2017Innospec BuyMonness, Crespi, Hardt & Co.
04.11.2016Innospec BuyMonness, Crespi, Hardt & Co.
DatumRatingAnalyst
09.11.2017Innospec NeutralMonness, Crespi, Hardt & Co.
19.12.2016Innospec NeutralMonness, Crespi, Hardt & Co.
12.10.2015Innospec NeutralMonness, Crespi, Hardt & Co.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Innospec IncShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"